Division of CVS Health Corp.
Latest From Coram LLC
Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced December 2013-January 2014.
Egalet secured Shionogi as its first major partner in a deal focused on abuse-deterring forms of hydrocodone; to complement its specialty pharmacy portfolio, CVS acquired the infusion therapy business Coram for $2.1 billion. A $729 million debt offering by Incyte made up nearly one-third of the $2.5 billion in biopharma financing; and sources of public fundraising have been increasing over the past few months in the device industry, which raised $532 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November through December 2013
- Infusion Therapy Equipment and Supplies
- Drug Delivery
- Therapeutic Areas
- Coram Healthcare Corp.
- North America
- Parent & Subsidiaries
- CVS Health Corp.
- Senior Management
John G Figueroa, CEO
Fred Stepan, CFO
Harriet Albery, Chief Commercial Officer
Keith Crawford, SVP, Strategic Initiatives & Bus. Dev.
- Contact Info
Phone: (800) 267-2642
555 17th St.
Denver, CO 80202
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.